Brigham Does Not Contest Plaintiffs’ Offers of Proof as Morcellation Cases Proceed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

This article is part of The Cancer Letter's How Medical Devices Do Harm series.

BRIGHAM & WOMEN’S HOSPITAL chose not to contest the plaintiffs’ offers of proof in two medical malpractice lawsuits against the Boston hospital at a Massachusetts tribunal May 13.

The two lawsuits related to power morcellation will now be allowed to proceed. The suits were filed by Richard Kaitz and Hooman Noorchashm, whose wives, Erica Kaitz and Amy Reed, had the controversial minimally invasive surgery at Brigham in 2012 and 2013, respectively.

The procedure, which until recently was performed in an estimated 100,000 women annually in the U.S., is the focal point of a two-year debate that has divided the surgical field. When a previously undiagnosed malignant tumor—usually a sarcoma—is present, the procedure spreads the cancerous tissue, upstaging the disease (The Cancer Letter, How Medical Devices Do Harm).

Erica died Dec. 7, 2013 from metastatic leiomyosarcoma, and Reed, formerly an anesthesiologist at Beth Israel Deaconess Medical Center, is undergoing treatment for stage IV disease.

“It’s a rare case that the defendant does not contest the plaintiff’s offer of proof at the tribunal stage,” said Tom Greene, the attorney representing Kaitz and Noorchashm’s families. Brigham did not respond to an email from The Cancer Letter by deadline.

Massachusetts law requires that a tribunal—consisting of a judge, an attorney, and a physician—review medical malpractice cases to screen out lawsuits that are not supported by clinical evidence or fact. The process determines whether there is sufficient evidence for the case to proceed.

According to the Massachusetts Medical Society, tribunals screen out approximately 16 percent of all medical malpractice cases in the state.

YOU MAY BE INTERESTED IN

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more
The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.
The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login